AU6153400A - Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients - Google Patents

Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients

Info

Publication number
AU6153400A
AU6153400A AU61534/00A AU6153400A AU6153400A AU 6153400 A AU6153400 A AU 6153400A AU 61534/00 A AU61534/00 A AU 61534/00A AU 6153400 A AU6153400 A AU 6153400A AU 6153400 A AU6153400 A AU 6153400A
Authority
AU
Australia
Prior art keywords
agonists
therapy
pharmaceutically acceptable
acceptable derivates
gabab receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61534/00A
Other languages
English (en)
Inventor
Giancarlo Colombo
Walter Fratta
Gian Luigi Gessa
Luca Pani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
L Molteni and C dei Fratelli Alitti Societa di Esercizio SpA
Original Assignee
Molteni and C SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molteni and C SpA filed Critical Molteni and C SpA
Publication of AU6153400A publication Critical patent/AU6153400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU61534/00A 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients Abandoned AU6153400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI001715A IT1313585B1 (it) 1999-07-30 1999-07-30 Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
ITMI99A001715 1999-07-30
PCT/EP2000/006120 WO2001008675A1 (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients

Publications (1)

Publication Number Publication Date
AU6153400A true AU6153400A (en) 2001-02-19

Family

ID=11383467

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61534/00A Abandoned AU6153400A (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients

Country Status (16)

Country Link
EP (1) EP1202727B1 (enExample)
CN (1) CN1176650C (enExample)
AT (1) ATE285763T1 (enExample)
AU (1) AU6153400A (enExample)
CA (1) CA2379752C (enExample)
DE (1) DE60017147T2 (enExample)
DK (1) DK1202727T3 (enExample)
ES (1) ES2235913T3 (enExample)
HK (1) HK1046849B (enExample)
IL (2) IL147876A0 (enExample)
IT (1) IT1313585B1 (enExample)
PL (1) PL196334B1 (enExample)
PT (1) PT1202727E (enExample)
RU (1) RU2262352C2 (enExample)
SI (1) SI1202727T1 (enExample)
WO (1) WO2001008675A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019163A2 (en) * 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP4498407B2 (ja) 2006-12-22 2010-07-07 キヤノン株式会社 プロセスカートリッジ、電子写真画像形成装置、及び、電子写真感光体ドラムユニット
JP5291123B2 (ja) 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
JP2012519212A (ja) 2009-03-03 2012-08-23 ゼノポート，インコーポレイティド Ｒ−バクロフェンプロドラッグの持効性放出経口投与形
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011081558A1 (ru) * 2009-08-21 2011-07-07 Komissarov Jury Vladimirovich Курительное устройство для отказа от табачного курения
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2019195813A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
RU2132203C1 (ru) * 1998-09-03 1999-06-27 Шакирзянов Галимзян Закирович Способ лечения табачной зависимости и антитабачный комбинированный препарат

Also Published As

Publication number Publication date
SI1202727T1 (enExample) 2005-08-31
CA2379752C (en) 2008-05-27
DE60017147T2 (de) 2006-01-12
CN1377265A (zh) 2002-10-30
PT1202727E (pt) 2005-05-31
DK1202727T3 (da) 2005-05-09
EP1202727A1 (en) 2002-05-08
ATE285763T1 (de) 2005-01-15
ITMI991715A0 (it) 1999-07-30
HK1046849B (en) 2005-07-15
IL147876A0 (en) 2002-08-14
RU2262352C2 (ru) 2005-10-20
DE60017147D1 (de) 2005-02-03
CN1176650C (zh) 2004-11-24
HK1046849A1 (en) 2003-01-30
IT1313585B1 (it) 2002-09-09
EP1202727B1 (en) 2004-12-29
ITMI991715A1 (it) 2001-01-30
PL353373A1 (en) 2003-11-17
WO2001008675A1 (en) 2001-02-08
CA2379752A1 (en) 2001-02-08
IL147876A (en) 2007-06-17
PL196334B1 (pl) 2007-12-31
ES2235913T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
AU6153400A (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MY130619A (en) Pharmaceutical formulations of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
MY146868A (en) Solid oral dosage forms of valsartan
PL366430A1 (en) Sustained release formulations of oxymorphone
AU1434000A (en) Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
DE602004030931D1 (enExample)
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO1999044608A8 (en) New use
MXPA04002714A (es) Uso de derivados de 2-oxo-1-pirrolidina para el tratamiento de trastornos del movimiento y de la discinesia.
MY122042A (en) Pro-drugs and counterparts of camptothecin, their application as medicines
IL136415A (en) Transmucosal formulations of levosimendan
GB9930077D0 (en) Medicaments
AU9028098A (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
AU2203101A (en) Formulations of adenosine a1 agonists
NZ538926A (en) Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases
MY127600A (en) Solid oral dosage forms of valsartan
MX9706759A (es) Uso de penciclovir para el tratamiento de virus deherpes 8 humano.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase